OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Marshall on the Importance of Testing for BRAF Mutations in mCRC

February 12th 2018

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the specificity now required in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Jarnagin on the Improvements in Surgery for Patients With mCRC

February 12th 2018

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.

Dr. Durand on the Management of Rhythm Disturbances Using Web-Based Technologies

February 12th 2018

Jean-Bernard Durand, MD, medical director of Cardiomyopathy Services, director of Cardiovascular Genetics Research, The University of Texas MD Anderson Cancer Center, discusses web-based management technologies for patients with cancer.

Dr. Shah on Cellular Therapies for Patients With Myeloma

February 12th 2018

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Comprehensive Cancer Center, discusses the potential of chimeric antigen receptor T-cell therapy in myeloma.

Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced CTCL

February 12th 2018

Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma.

Dr. Haldorsen on Overcoming Challenges With Imaging in Endometrial Cancer

February 9th 2018

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, on overcoming challenges with imaging in endometrial cancer.

Dr. Wang Discusses Treatment Options for FLT3-Mutated AML

February 9th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses treatment options for patients with FLT3-mutated acute myeloid leukemia.

Dr. Chau on Findings of Ramucirumab Plus Pembrolizumab in Gastric/GEJ Cancer

February 9th 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses finding with the combination of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

Dr. Andreadis Discusses Toxicities With CAR T-Cell Therapy

February 8th 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses toxicities associated with CAR T-cell therapy.

Dr. Overman Discusses Immunotherapy and MSI Testing in CRC

February 8th 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy and microsatellite instability (MSI) testing in colorectal caner (CRC).

Dr. Tam Discusses the Side Effect Profile of Duvelisib in CLL

February 8th 2018

Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses the side effect profile of duvelisib in patients with chronic lymphocytic leukemia (CLL).

Dr. Carey Discusses Findings From the CALGB40502 Trial in TNBC

February 7th 2018

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses findings from the CALGB 40502/NCCTG N063H trial in triple-negative breast cancer.

Dr. Morgan on Combinations With PARP Inhibitors in Prostate Cancer

February 7th 2018

Alicia Morgan, MD, Mather Hospital, discusses combinations with PARP inhibitors in prostate cancer.

Dr. Markman on Overall Survival as an Endpoint in Ovarian Cancer Trials

February 7th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses overall survival as an endpoint in ovarian cancer clinical trials.

Dr. Locke Discusses Long-Term Follow-Up of ZUMA-1 Trial for NHL

February 7th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses long-term follow-up results of the ZUMA-1 trial for patients with non-Hodgkin lymphoma (NHL).

Dr. Kaplan Discusses Combinations With Rituximab for MCL

February 7th 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses combinations with rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).

Dr. Bustoros on Next-Generation Sequencing in Multiple Myeloma

February 7th 2018

Mark W. Bustoros, MD, Dana-Farber Cancer Institute, discusses the role of next-generation sequencing for patients with multiple myeloma.

Dr. Huang on the Widespread Adoption of Robotic Surgery for Bladder Surgery

February 7th 2018

William C. Huang, MD, associate professor, department of Urology, co-director, Robotics Program, Chief Urology Service, Tisch Hospital, NYU Langone Health, discusses misconceptions regarding robotic-assisted bladder surgery.

Dr. Smith on Acquired Resistance to Targeted Agents for AML

February 7th 2018

Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient acquired resistance in quizartinib (AC220) and gilteritinib (ASP2215) in acute myeloid leukemia (AML).

Dr. Crane on the Use of Proton Therapy and the MR-Linear Accelerator in GI Malignancies

February 7th 2018

Christopher Crane, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the emergence and success of new technologies in the treatment of patients with gastrointestinal (GI) malignancies.